Biotech Values

[DewDiligence]

TEVA MNTA – That may be another benefit of the new formulation, but I think Teva is more concerned about a generic Copaxone in the US than they are about competition from the new oral meds.

Let me put this another way: If not for the threat of a generic, I doubt that Teva would've embarked on the program to develop a low-volume formulation.